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Urinary bladder outlet obstruction can cause lower urinary tract symptoms in men and women, such 
as a weak or interrupted urine stream, straining to void, hesitancy, and the feeling of incomplete 
bladder emptying. These symptoms can also be associated with underactive bladder syndrome. This 
urological condition has a high prevalence in both genders, especially in older age groups. The most 
common risk factors that can contribute to the pathogenesis of underactive bladder syndrome are 
aging, detrusor myopathy, neuroinflammatory, neurodegenerative and other lesions of the central 
and peripheral nervous system, and diabetes mellitus. Reduced detrusor contractility, or detrusor 
underactivity, is the most common pathology of underactive bladder syndrome. Detrusor 
underactivity is a urodynamic definition provided by the International Continence Society. The 
urodynamic trace is characterised by a low urine flow rate accompanied by low detrusor pressure or 
brief detrusor muscle contraction. Underactive bladder syndrome is often recognised and treated 
poorly in clinical practice because the symptoms are not specific. Furthermore, underactive bladder 
can be asymptomatic or coexist with bladder outlet obstruction and overactive bladder syndrome. 
The aim of this study was to review recent research concerning the aetiology, classification, 
diagnostic evaluation, and available treatment methods for patients with symptoms of underactive 
bladder syndrome. Making an accurate underactive bladder diagnosis is challenging because it is a 
multifactorial condition with various patterns of manifestation. Consequently, there is still no general 
agreement and standardisation regarding the most favourable diagnostic and therapeutical 
approach. 
(Radoja I. Underactive Bladder Syndrome: An Often Overlooked Condition. SEEMEDJ 2021; 5(1); 109-
121) 
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Introduction 
The storage and excretion of urine in women 
and men depend on the coordinated activity of 
the neural centres, smooth muscles of the 
bladder and urethra, and the urethral striated 
muscle (1). Various urological and neurological 
diseases can cause voiding dysfunction, which 
manifests with lower urinary tract symptoms 
(LUTS), clinical signs, and syndromes (2). 
Straining to void, a weak urine stream, hesitancy, 
and other LUTS during the voiding phase of 
micturition are prevailing symptoms that 
urologists encounter in an outpatient and clinical 
setting. These LUTS are more often present in 
men than in women and are commonly 
associated with bladder outlet obstruction (BOO) 
(3). Benign prostatic hyperplasia (BPH) and 
urethral stricture are the usual suspects in men, 
while in women, the most common causes of 
BOO are functional sphincteric obstruction, anti-
incontinence surgery, urethral stricture and 
pelvic organ prolapse (4, 5). These symptoms 
may be a consequence of detrusor underactivity 
(DUA) (6). DUA is caused by reduced detrusor 
contractility, which can be idiopathic or result 
from various neurological, urological, 
autoimmune, muscular, and other diseases (7, 8). 
According to the International Continence 
Society (ICS) terminology, DUA is a diagnosis 
based on urodynamic investigations (9). DUA is 
characterised by a low urine flow rate 
accompanied by low detrusor pressure, brief 
detrusor contraction, or absent detrusor 
contraction (10). The result of this is prolonged 
micturition, failure to achieve complete bladder 
emptying in an expected time interval, and a 
high bladder post-void residual volume (PVR).  
Underactive bladder syndrome (UAB) is a 
contemporary clinical term that describes 
symptomatic DUA as a cause of voiding 
dysfunction (11, 12). UAB is defined as a complex 
of voiding symptoms, such as a weak urine 
stream, straining to void, and hesitancy (13, 14). 
Storage and post-micturition symptoms, such as 
a reduced sensation of bladder filling, terminal 
dribbling, and a feeling of incomplete bladder 
emptying may also be present, with or without 
PVR (15). It can be challenging to distinguish if 
BOO or UAB is the problem because these 
conditions have similar symptoms and they can 
coexist and intertwine, especially in men with 
BPH (16). UAB is not so popular when compared 
with overactive bladder syndrome (OAB) and 
these two syndromes may be present at the 
same time (17).  
Detrusor overactivity (DOA) is another 
urodynamic diagnosis and OAB represents 
symptomatic DOA (18). DOA is characterised by 
involuntary detrusor contractions during the 
filling phase, which can be spontaneous or 
provoked during a urodynamic study (9). OAB 
consists of storage LUTS and it is defined as 
urinary urgency, with or without urgency 
incontinence, usually with increased daytime 
frequency and nocturia, if there is no proven 
infection or obvious pathology (19). We are 
better acquainted with the pathophysiology and 
diagnostic approach of OAB compared to UAB 
(20). Also, OAB treatment methods are more 
efficient and safer (21). Storage, voiding and 
postmicturition LUTS are associated with 
significant morbidity and mortality of men and 
women aged 65 and over. For example, nocturia 
associated with BPH and OAB can lead to a fall-
related bone fracture, persistently high PVR 
associated with UAB can cause bilateral 
hydronephrosis, chronic cystitis, overflow 
incontinence, and formation of bladder stones, 
which can seriously affect the quality of life 
(QOL) (22-25).  
Despite new research initiatives and the latest 
information about UAB and DUA, there is still no 
consensus on a diagnostic and therapeutical 
approach. Furthermore, assessment can be 
different in men and women. If we could reach a 
general agreement on diagnosing UAB and 
DUA, then we could establish the parameters of 
non-invasive assessment tools, for example, a 
combination of UAB symptom score 
questionnaire, ultrasound measurement of 
detrusor wall thickness, and uroflowmetry result 
(26). This could help us distinguish patients with 
UAB and DUA from those with BOO and BPH.  
The aim of this review was to describe the 
clinical and urodynamic aspects of UAB and to 
emphasise the latest insights in the diagnostic 
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evaluation and available UAB treatment 
methods. 
Prevalence of underactive bladder 
syndrome  
The prevalence rates vary because UAB is often 
a poorly recognised condition in clinical practice, 
frequently mistaken for BOO, and usually not 
associated with a possible neurological 
condition. The reason for this is that there is no 
classification of UAB and a definitive diagnosis 
can be achieved only by conducting a 
urodynamic study. According to previous 
research, UAB has a high prevalence in both 
genders, especially in older age groups. UAB 
has the potential of being a serious public health 
problem in the future because it is expected that 
the percentage of people aged 65 and over will 
approach 20% of the total population by 2050 (13, 
27). Also, neurodegenerative disorders and other 
neurologic conditions that can lead to LUTS and 
UAB increase in prevalence with age (28). The 
prevalence of UAB in men under the age of 50 
ranges from 9% to 28% and increases with age, 
affecting 48% of men over the age of 70 (6). The 
prevalence of UAB is approximately 12% in 
younger women and 45% in older female 
patients (29). One epidemiological survey, which 
included a total of 633 participants aged 60 and 
over, showed that 23% of them had voiding and 
post-micturition LUTS, with no difference 
regarding gender or age; however, only 11% of 
the participants heard about UAB (30). In another 
original scientific study, urodynamic testing was 
performed on 1,179 patients with LUTS aged 
over 65. After the evaluation of the results, it was 
established that out of 40.2% of men and 13.3% of 
women who had DUA, 72.6% of the women with 
DUA had DOA or stress urinary incontinence 
(SUI) and 46.5% of men with DUA also had DOA 
or BOO (31). 
 
Aetiology of underactive bladder 
syndrome  
There are many diseases that alone or combined 
cause bladder innervation disorders and/or 
damage to the detrusor muscle. This can lead to 
the inability of the detrusor muscle to generate 
sufficient intravesical pressure to empty the 
urinary bladder. Therefore, the aetiology of UAB 
is multifactorial and the most important 
aetiological factors are age-related factors, 
neurological disorders, BOO, and diabetes 
mellitus (DM) (32). If there is no specific cause, 
UAB can be classified as idiopathic, which is 
more common in younger patients (33). Older 
people are more likely to develop UAB 
symptoms. The amount of acetylcholine 
esterase-positive nerves in the bladder 
decreases with age and a reduced response to 
bladder filling in the insular cortex occurs (34, 35). 
Also, the proportion of collagen fibres increases 
with age and the number of smooth muscle cells 
and muscarinic receptors decreases (34, 36). 
Neurological diseases account for the largest 
share of risk factors for lower urinary tract 
disorders such as OAB and UAB. Patients could 
have LUTS but no formally diagnosed 
neurological condition. LUTS could be an early 
symptom in the manifestation of an underlying 
neurological disease, which is referred to as 
“occult neurology” (37). If we fail to identify an 
undiagnosed neurological aetiology, we risk 
poor outcomes for LUTS treatment. OAB 
symptoms are more common in patients who 
have had an acute cerebrovascular accident 
(CVA) and in patients with multiple sclerosis (MS) 
and Parkinson’s disease, but UAB symptoms and 
high PVR have also been reported (38-40). 
Urinary retention and DUA can occur in early 
stages of Guillain-Barré syndrome, but long-
term LUTS are not so common.  
Traumatic, degenerative and other spinal cord 
injuries can also cause voiding dysfunction. 
Symptomatology depends on the spinal cord 
injury level. Spinal cord injuries below the sacral 
micturition centre (SMC), which is located in the 
intermediolateral grey of the sacral cord from 
S2-S4, are most often partial, resulting in 
weakened bladder contractility and UAB 
symptoms. Partial or complete injuries above the 
SMC and neuroinflammatory and 
neurodegenerative diseases of the central 
nervous system often result in the appearance 
of OAB symptoms. Infectious diseases, such as 
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neurosyphilis, herpes zoster, herpes simplex, 
and acquired immunodeficiency syndrome, are 
also associated with a neurological dysfunction 
that causes the symptoms of UAB and/or OAB 
(41-44). Radical prostatectomy, radical 
hysterectomy, and other pelvic surgical 
procedures, in which peripheral nerve damage 
may occur, are examples of an iatrogenic cause 
of UAB (35). Even OAB and BOO can cause 
structural changes of the urinary bladder over 
time, which include a reduction in detrusor 
blood flow, detrusor muscle deterioration, and 
proliferation of connective tissue, which can lead 
to DUA and UAB (45).  
DM is one of the most common diseases in 
general population, which has recently reached 
epidemic proportions in many countries and is 
associated with numerous complications and 
organ damage (46). One of the more common 
complications of DM is diabetic cystopathy (DC) 
(47). The prevalence of DC ranges from 20 to 
90% (48). As with UAB, we still lack a 
standardised diagnostic assessment of DC. The 
symptoms include an impaired sensation of 
bladder fullness, reduced bladder contractility, 
increased bladder capacity, and increased PVR. 
DC can be asymptomatic early in the course of 
DM (49). DC is a result of sensory and autonomic 
polyneuropathy, microvascular damage, 
dysfunction of detrusor smooth muscle cells, 
and dysfunction of urothelial cells (50). Urothelial 
cells were considered to be just a barrier 
between the urinary tract lumen and underlying 
tissues of the urinary tract wall, but they have a 
more active role in bladder physiology. These 
cells form a functional unit that responds to 
external events by releasing adenosine 
triphosphatase, nitric oxide, and prostaglandins 
(51, 52). These modulator agents regulate the 
activity of afferent nerves and the detrusor 
smooth muscle and process the information 
about the urinary tract chemical and physical 
status (e.g. luminal pressure, urine composition) 
(53). With all this said, it just goes to show that we 
still have a lot to learn about the function of the 
lower urinary tract and surrounding tissues. 
 
Diagnostic evaluation of underactive 
bladder syndrome 
The symptoms of UAB are not specific and they 
can overlap with other voiding dysfunctions, 
especially with BOO. The symptoms that may be 
suggestive of UAB include hesitancy or a delay 
in passing urine, weak or thin urine stream, 
interrupted urine flow, post-void dribbling of 
urine, feeling of having to go again after the 
stream has stopped, voiding a second or even 
multiple times after the initial voiding has 
completed, having to strain to facilitate voiding, 
and frequent urination day and night in small 
volumes (54). With history-taking and a physical 
examination in medical practice, we can only 
assume that an observed patient has UAB. It is 
especially important to consider neurological 
symptoms and diseases. During a physical 
examination, we palpate the suprapubic region 
to check the pain and fullness of the bladder. 
Also, we assess the tone of the anal sphincter, 
perianal sensation, bulbocavernosus reflex, and 
plantar reflex, which can be compromised, 
absent, or significantly diminished (55, 56). Some 
studies have examined the usefulness of non-
invasive methods, such as flow pattern on 
uroflowmetry, intravesical prostatic protrusion 
(IPP), PVR volume, and bladder voiding 
efficiency (BVE) to distinguish between UAB and 
BOO (15, 57).  
Non-invasive methods are very useful for the 
assessment of patients who cannot go through 
invasive urodynamic testing. Uroflowmetry is a 
simple and non‐invasive urodynamic test of 
measuring and recording the voided volume, 
urinary flow rate, and wave shape throughout 
micturition (58). It is a screening procedure and 
its results may be indicative of BOO or UAB. IPP 
is measured during almost every examination of 
men with LUTS. It is measured using the 
transabdominal ultrasound in the sagittal view 
and defined as the vertical distance from the tip 
of the protrusion to the base of the prostate (59, 
60). Regarding this distance, IPP can be 
quantified into three grades, which more or less 
correlate with the symptoms related to BOO: 
grade 1 (≤ 5 mm), grade 2 (5-10 mm), grade 3 (≥ 
10 mm). PVR is measured immediately after 
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voiding by ultrasound or by inserting a catheter 
into the bladder through the urethra. Using 
ultrasound, we measure three dimensions of the 
bladder: maximal transverse (width), anterior-
posterior (height), and longitudinal (length). Then 
we determine the PVR volume using the Dicuio’s 
formula (volume [mL] = height [cm] × depth [cm] 
× transverse diameter [cm] × 0.52) (61). To 
determine BVE, we measure the bladder 
volume before voiding (BVvoid) using 
ultrasound and then we measure voided volume 
(VV) using a measuring cylinder. Using the 
equation ([VV/BVvoid ] × 100), we can express 
BVE by fraction (%) of the voided volume. A 
combination of lower IPP (< 8.2 mm) and lower 
BVE (< 70), sawtooth and interrupted wave 
shape on uroflowmetry might be useful factors 
to predict DU and UAB.  
Despite all non-invasive methods, pressure-flow 
study is practically the only method by which we 
can establish an accurate diagnosis of UAB (62). 
The parameters observed during this study are 
peak flow (Qmax) and detrusor pressure at peak 
flow (PdetQmax) (63). Using these parameters, 
we can assess the contractility of the bladder by 
using the bladder contractility index (BCI) 
formula according to the equation 
Pdet@Qmax+5Qmax (64). With this formula, we 
can divide bladder contractility into strong (BCI > 
150), normal (BCI 100–150), and weak (BCI < 100). 
Also, we can exclude or confirm the presence of 
the obstruction in men using the bladder outlet 
obstruction index (BOOI) formula according to 
the equation Pdet@Qmax-2Qmax (65). Based on 
the results of the BOOI formula, men can be 
divided into obstructed (BOOI > 40), equivocal 
(BOOI 20−40), and unobstructed (BOOI < 20). 
BOOI formula does not apply to women. At the 
moment, the Blaivas and Groutz nomogram is 
the most common method used to define BOO 
in women as a Qmax < 12 mL/sec combined with 
a Pdet@Qmax of  > 20 cm H2O in a pressure-flow 
study (66). There is a potential future test for 
UAB that includes urine biomarkers, such as 
nerve growth factor, and bladder wall biopsy 
with an electron-microscopic histopathologic 
ultrastructural assessment of the detrusor (67, 
68). The research of these diagnostic methods is 
still ongoing, so further studies are needed to 
implement them into clinical practice. 
Treatment of underactive bladder 
syndrome 
The treatment of UAB is focused on improving 
the QOL and preventing complications. If the 
patients are asymptomatic, we still need to 
administer the treatment. Also, we must inform 
patients about possible side effects of each type 
of treatment. It is necessary to achieve the status 
of an empty bladder regardless of the aetiology 
of UAB to avoid chronic urinary retention, 
bilateral hydronephrosis, recurrent urinary tract 
infections (UTI), bladder stone formation, and 
overflow incontinence. Common methods of 
treatment are timed voiding, double voiding, 
straining to void, Credé or Valsalva manoeuvre, 
clean intermittent catheterisation (CIC), 
pharmacotherapy, and surgical treatment (35, 
69, 70). 
 In patients with vesicoureteral reflux and high 
intravesical pressure, the Credé and Valsalva 
manoeuvres are contraindicated. Constipation 
should be avoided by dietary fibre intake and 
exercise, which are usually recommended as 
first-line treatment (71). Prolonged use of 
laxatives may lead to some adverse effects. CIC 
must be recommended to patients who have 
chronic urinary retention with high PVR. If  
possible, placement of an indwelling urinary 
catheter and suprapubic cystostomy should be 
avoided due to complications, such as catheter 
encrustation, urethral erosion, and increased risk 
of UTI and bladder cancer (72). We need to 
explain the benefits of CIC to each patient to 
enhance compliance. Silicone catheters are 
most commonly used because they carry a 
lower risk of allergic reactions. Patients can 
perform catheterisation on their own or they are 
catheterised by caregivers. Recommended daily 
number of catheterisations ranges between 4 
and 6 and the amount of urine discharged at 
every catheterisation should not exceed 400–
500 ml. Silicone catheters are most commonly 
used. CIC is impractical and inconvenient for 
elderly, visually impaired and mentally 
handicapped patients, and for patients with 
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limited manual dexterity. Complications of CIC 
are urethral injuries (e.g. false passage, 
strictures), UTI, and haematuria (73).  
There are no effective oral drugs for UAB 
treatment. Contemporary pharmacotherapy of 
UAB includes the use of α-adrenergic blockers 
to reduce outlet resistance at the level of the 
bladder neck and muscarinic agonists or choline 
esterase inhibitors to increase detrusor 
contraction (74). These drugs can be used as 
monotherapy or in combination. α-adrenergic 
blockers, such as tamsulosin at a dose of 0.4 mg 
once a day and silodosin at a dose of 8 mg once 
a day, are in most cases considered for the initial 
stage of UAB treatment in men (75). α-
adrenergic blocker therapy for women with UAB 
is an off-label regimen in most countries (76). 
Bethanechol chloride (BC) and pyridostigmine 
bromide (PB) are the most common orally 
administered parasympathomimetic agents 
used in clinical practice (77). The usual adult oral 
dose for BC ranges from 10 to 50 mg three or 
four times a day and from 60 to 180 mg for PB. 
Their effectiveness is limited due to the 
downregulation of muscarinic receptors and 
potentially life-threatening side-effects, such as 
bradycardia and ventricular tachycardia (32). The 
European Association of Urology (EAU) states 
that they should not be prescribed for UAB 
treatment (75). Prostaglandin E2 (PGE2) can 
increase the inotropic activity in smooth muscles 
(72). It prevents the release of noradrenaline 
from sympathetic nerve endings. Intravesical 
administration of PGE2 can increase detrusor 
contractions and decrease maximal urethral 
closure pressure (75). The effectiveness of PGE2 
is limited and it is not recommended for routine 
treatment.  
Onabotulinumtoxin A injections into the external 
urinary sphincter reduce urethral resistance, 
eliminate the inhibitory effects of urethral 
afferent nerves on the detrusor and allow easier 
voiding with the aid of increased abdominal 
pressure (72). This therapy has not been 
approved yet and there is no standard dosage. 
The efficacy of transurethral resection of the 
prostate and transurethral incision of the bladder 
neck in patients with BOO and accompanying 
UAB is questionable. Patients should be 
informed that they may not benefit from this 
type of procedure. 
Chronic urinary retention associated with UAB 
often leads to myogenic decompensation 
because of an overdistended bladder. 
Reduction cystoplasty decreases the capacity of 
the bladder and facilitates bladder emptying, 
but it does not increase bladder contractility (72, 
75). This treatment method should be performed 
only in well-chosen cases and in patients with 
residual detrusor contractility. Sacral 
neuromodulation therapy (SNM) is appropriate 
for well-chosen patients who have not been 
helped by more conservative treatments, such 
as drug therapy (78). SNM uses a surgically 
implanted device to send electrical impulses to 
the sacral nerves located in the lower back, 
which modify the function of the detrusor 
muscle and pelvic floor muscles. It is one of the 
more expensive methods of treatment and it is 
performed in specialised high-volume tertiary 
referral centres. Transurethral intravesical 
electrical stimulation and use of the stem cells 
are novel treatment methods with reports that 
they can improve detrusor contractility and 
increase weak individual myocyte contractility 
(79). Neurovascular latissimus dorsi (LD) detrusor 
myoplasty is suitable for motivated young 
patients who do not want to undergo CIC. The 
LD muscle flap is wrapped around the bladder, 
attached to the pelvic fascia and ligaments, and 
it is anastomosed to the deep inferior epigastric 
vessels and lowest motor branches of the 
intercostal nerve (80). LD detrusor myoplasty 
can adequately restore bladder emptying on 
demand (81). Further studies are needed to 
implement these surgical and novel treatment 
methods in clinical practice. Regardless of the 
type of treatment used, patients should have 
frequent follow-ups with repeated urodynamic 
examination where necessary. 
Discussion 
ICS conducted a comprehensive review of the 
terminology pertaining to the lower urinary tract 
function and dysfunction and recommended the 
use of the term DUA (9). UAB has not yet been 
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defined by the ICS. Furthermore, the current 
definitions of both conditions do not include 
possible aetiological risk factors. Based on the 
aetiology, UAB can be classified into four types: 
neurogenic, myogenic, and idiopathic (29). 
Neurogenic UAB is associated with changes in 
the afferent and efferent signals of the 
micturition reflex (82). Myogenic UAB is 
associated with modified contraction 
mechanisms of detrusor muscle cells, which can 
result in reduced autonomous activity of the 
bladder (83). UAB can be the combination of 
myogenic and neurogenic factors or a 
combination of two or more neurogenic factors. 
Idiopathic UAB has an unknown cause or 
mechanism of apparent spontaneous origin (84).  
Based on urodynamic findings, UAB can be 
classified into three types: DU, acontractile 
detrusor, and OAB/UAB combination (29). 
Patients with DUA have impaired detrusor 
contractility and can void incompletely or they 
have no urine flow during the urodynamic 
examination. If there are no detrusor 
contractions during cystometry and a pressure-
flow study, then we are talking about an 
acontractile detrusor. It is an extreme type of 
DUA, patients have high PVR, and the emptying 
of the bladder is performed by increased 
abdominal pressure or CIC. It is important to note 
that some patients have UAB and OAB 
symptoms (17). If we suspect this is the case, a 
urodynamic assessment is mandatory. DOA is 
recorded during filling cystometry and DUA 
during a pressure-flow study. Education about 
the symptoms and clinical signs of the lower 
urinary system is of utmost importance for all 
urologists, urogynecologists, and 
neurourologists. Taking a medical history in an 
outpatient setting can be complicated at times 
and for this reason, it is recommended to use 
questionnaires, frequency-volume charts, and 
bladder diaries in the evaluation of symptoms. 
Physicians must also be well acquainted with 
performing a physical examination, especially of 
neurological status. Urodynamic testing is very 
demanding and one must be very familiar with 
the methodology to adequately interpret the 
results. Catheter placement and recording of 
urodynamic traces must be performed 
according to the ICS standards. There is still no 
effective pharmacotherapy of UAB. For now, CIC 
is the only effective therapy for achieving empty 
bladder status, but unfortunately, not all patients 
are willing to perform the catheterisation 
procedure multiple times a day for an extended 
period of time. All patients should be offered 
treatment taking into account the cause of UAB 
and the most distinct symptomatology. CIC is 
the main treatment method in the management 
of patients with high PVR and UAB. 
Contemporary research has shown that there 
are drugs which can have a positive effect on 
DUA, but in most cases, these studies were not 
randomised clinical trials. Oral 
parasympathomimetics can improve detrusor 
contractions and facilitate bladder emptying, but 
they do not have a long-lasting effect and they 
have many serious side effects. ICS and EAU 
guidelines do not recommend or approve the 
use of parasympathomimetics for UAB. This 
therapy is contraindicated in patients with 
coexisting OAB and UAB symptoms because it 
may worsen bladder emptying, leading to urine 
retention and UTI. Therefore, we must perform a 
thorough neurourologic and urodynamic 
assessment if we suspect that there are multiple 
voiding dysfunctions in one patient at the same 
time. α-adrenergic blockers are useful in men 
with BOO accompanied by PVR, but their use in 
women with UAB is not supported by the 
guidelines. SNM and reconstructive surgical 
methods are expensive and usually performed 
in experienced high-volume centres. A large 
number of patients diagnosed with UAB 
sometimes do not have access to such centres 
due to distance or cost of treatment. Research is 
underway on possible new 
pharmacotherapeutics and new surgical 
methods of treating UAB. 
Conclusion 
Regardless of the complexity of the 
neuromuscular mechanism of controlling the 
storage of urine and emptying the bladder, we 
take the process of voiding for granted. When 
some form of voiding dysfunction occurs, 
patients experience how much it can affect the 
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QOL (85). UAB is a relatively new term of voiding 
dysfunction and was recognised in some 
aspects years before we knew what it is today. It 
has a high prevalence in the elderly population 
(86). Despite new insights, UAB is still shrouded 
in mystery (6). Many diseases can cause the loss 
of sensation in the bladder and/or detrusor 
muscle damage (8). It is a great challenge to 
determine exactly which disease caused the 
symptoms of UAB. We must do our best to 
identify the most likely aetiology of UAB in each 
patient. Classification of UAB needs to be 
improved to facilitate diagnostic processing and 
it should be based on aetiology, urodynamic 
findings, and symptoms. At this point, we have a 
great knowledge about the symptoms of UAB 
and about the urodynamic characteristics of 
DUA. This can improve through further research 
on the pathophysiology of UAB. Future 
developments in the pharmaceutical industry, 
gene therapy, and biomedical applications are 
expected to close the gap in treatment. We 
need to raise awareness among those patients 
who are highly likely to develop UAB in order to 
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